India, June 15 -- QIAGEN N.V. (QGEN) and Incyte (INCY) announced a collaboration to develop a new diagnostic panel that will support Incyte's experimental therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. This includes Incyte's monoclonal antibody, INCA033989, which targets mutant calreticulin (mutCALR) and is being developed for myelofibrosis (MF) and essential thrombocythemia (ET).
As per the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-...